The efficacy of topoisomerase II-targeted anticancer agents reflects the persistence of drug-induced cleavage complexes in cells

Biochemistry

Volumn 47, Issue 45, 2008, Pages 11900-11908

  Bandele, Omari J ^a   Osheroff, Neil ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL CULTURE; CELLS; DNA; DRUG THERAPY; GENES; NUCLEIC ACIDS; ORGANIC ACIDS;

ANTI CANCER AGENTS; ANTI-CANCER DRUGS; CELL VIABILITIES; CELLULAR PROCESSES; CHEMOPREVENTATIVE; CONTINUOUS EXPOSURES; CULTURED HUMAN CELLS; CYTOTOXIC; DNA CLEAVAGES; EQUIVALENT TIMES; ETOPOSIDE; GENISTEIN; GENOTOXIC EFFECTS; HUMAN TOPOISOMERASE; IN CELLS; IN VITRO; IN VITRO STUDIES; ISOFORM; RECOVERY CYCLES; TOPOISOMERASE II; TYPE II;

CYTOLOGY;

ANTINEOPLASTIC AGENT; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; DNA TOPOISOMERASE (ATP HYDROLYSING); ETOPOSIDE; FLAVONOID; GENISTEIN; HISTONE H2AX; TOPOISOMERASE IIALPHA; TOPOISOMERASE IIBETA; UNCLASSIFIED DRUG;

ARTICLE; CELL VIABILITY; COMPLEX FORMATION; CONTROLLED STUDY; DNA CLEAVAGE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG EXPOSURE; DRUG TARGETING; GENOTOXICITY; HALF LIFE TIME; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; COMET ASSAY; DNA; DNA DAMAGE; DNA TOPOISOMERASES, TYPE II; ETOPOSIDE; GENISTEIN; HUMANS;

EID: 55849119882     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi800981j     Document Type: Article

References (60)

1. Berger, J. M., Gamblin, S. J., Harrison, S. C., and Wang, J. C. (1996) Structure and mechanism of DNA topoisomerase II. Nature 379, 225-232.
2. Nitiss, J. L. (1998) Investigating the biological functions of DNA topoisomerases in eukaryotic cells. Biochim. Biophys. Acta 1400, 63-81.
3. Fortune, J. M., and Osheroff, N. (2000) Topoisomerase II as a target for anticancer drugs: When enzymes stop being nice. Prog. Nucleic Acid Res. Mol. Biol. 64, 221-253.
4. Champoux, J. J. (2001) DNA topisomerases: Structure, function, and mechanism. Annu. Rev. Biochem. 70, 369-413.
5. Wang, J. C. (2002) Cellular roles of DNA topoisomerases: A molecular perspective. Nat. Rev. Mol. Cell Biol. 3, 430-440.
6. McClendon, A. K., and Osheroff, N. (2007) DNA topoisomerase II, genotoxicity, and cancer. Mutat. Res. 623, 83-97.
7. Liu, L. F., Rowe, T. C., Yang, L., Tewey, K. M., and Chen, G. L. (1983) Cleavage of DNA by mammalian DNA topoisomerase II. J. Biol. Chem. 258, 15365-15370.
8. Sander, M., and Hsieh, T. (1983) Double strand DNA cleavage by type II DNA topoisomerase from Drosophila melanogaster. J. Biol. Chem. 258, 8421-8428.
9. Zechiedrich, E. L., Christiansen, K., Andersen, A. H., Westergaard, O., and Osheroff, N. (1989) Double-stranded DNA cleavage/religation reaction of eukaryotic topoisomerase II: Evidence for a nicked DNA intermediate. Biochemistry 28, 6229-6236.
10. Hande, K. R. (1998) Etoposide: Four decades of development of a topoisomerase II inhibitor. Eur. J. Cancer 34, 1514-1521.
11. Li, T. K., and Liu, L. F. (2001) Tumor cell death induced by topoisomerase-targeting drugs. Annu. Rev. Pharmacol. Toxicol. 41, 53-77.
12. Walker, J. V., and Nitiss, J. L. (2002) DNA topoisomerase II as a target for cancer chemotherapy. Cancer Invest. 20, 570-589.
13. Baldwin, E. L., and Osheroff, N. (2005) Etoposide, topoisomerase II and cancer. Curr. Med. Chem. Anticancer Agents 5, 363-372.
14. Felix, C. A. (1998) Secondary leukemias induced by topoisomerase-targeted drugs. Biochim. Biophys. Acta 1400, 233-255.
15. Leone, G., Voso, M. T., Sica, S., Morosetti, R., and Pagano, L. (2001) Therapy related leukemias: Susceptibility, prevention and treatment. Leuk. Lymphoma 41, 255-276.
16. Felix, C. A. (2001) Leukemias related to treatment with DNA topoisomerase II inhibitors. Med. Pediatr. Oncol. 36, 525-535.
17. Felix, C. A., Kolaris, C. P., and Osheroff, N. (2006) Topoisomerase II and the etiology of chromosomal translocations. DNA Repair 5, 1093-1108.
18. Kurzer, M. S., and Xu, X. (1997) Dietary phytoestrogens. Annu. Rev. Nutr. 17, 353-381.
19. Galati, G., and O'Brien, P. J. (2004) Potential toxicity of flavonoids and other dietary phenolics: Significance for their chemopreventive and anticancer properties. Free Radical Biol. Med. 37, 287-303.
20. Yao, L. H., Jiang, Y. M., Shi, J., Tomas-Barberan, F. A., Datta, N., Singanusong, R., and Chen, S. S. (2004) Flavonoids in food and their health benefits. Plant Foods Hum. Nutr. 59, 113-122.
21. Sang, S., Hou, Z., Lambert, J. D., and Yang, C. S. (2005) Redox properties of tea polyphenols and related biological activities. Antioxid. Redox Signaling 7, 1704-1714.
22. Siddiqui, I. A., Adhami, V. M., Saleem, M., and Mukhtar, H. (2006) Beneficial effects of tea and its polyphenols against prostate cancer. Mol. Nutr. Food Res. 50, 130-143.
23. Ross, J. A., Potter, J. D., Reaman, G. H., Pendergrass, T. W., and Robison, L. L. (1996) Maternal exposure to potential inhibitors of DNA topoisomerase II and infant leukemia (United States): A report from the Children's Cancer Group. Cancer, Causes Control 7, 581-590.
24. Strick, R., Strissel, P. L., Borgers, S., Smith, S. L., and Rowley, J. D. (2000) Dietary bioflavonoids induce cleavage in the MLL gene and may contribute to infant leukemia. Proc. Natl. Acad. Sci. U.S.A. 97, 4790-4795.
25. Spector, L. G., Xie, Y., Robison, L. L., Heerema, N. A., Hilden, J. M., Lange, B., Felix, C. A., Davies, S. M., Slavin, J., Potter, J. D., Blair, C. K., Reaman, G. H., and Ross, J. A. (2005) Maternal diet and infant leukemia: The DNA topoisomerase II inhibitor hypothesis: A report from the children's oncology group. Cancer Epidemiol. Biomarkers Prev. 14, 651-655.
26. Austin, C. A., Patel, S., Ono, K., Nakane, H., and Fisher, L. M. (1992) Site-specific DNA cleavage by mammalian DNA topoisomerase II induced by novel flavone and catechin derivatives. Biochem. J. 282, 883-889.
27. van Waalwijk van Doorn-Khosrovani, S. B., Janssen, J., Maas, L. M., Godschalk, R. W., Nijhuis, J. G., and van Schooten, F. J. (2007) Dietary flavonoids induce MLL translocations in primary human CD34+ cells. Carcinogenesis 28, 1703-1709.
28. Bandele, O. J., and Osheroff, N. (2007) Bioflavonoids as poisons of human topoisomerase IIα and IIβ. Biochemistry 46, 6097-6108.
29. Bandele, O. J., and Osheroff, N. (2008) (-)-Epigallocatechin gallate, a major constituent of green tea, poisons human type II topoisomerases. Chem. Res. Toxicol. 21, 936-943.
30. Azarova, A. M., Lyu, Y. L., Lin, C. P., Tsai, Y. C., Lau, J. Y., Wang, J. C., and Liu, L. F. (2007) Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies. Proc. Natl. Acad. Sci. U.S.A. 104, 11014-11019.
31. Lyu, Y. L., Kerrigan, J. E., Lin, C. P., Azarova, A. M., Tsai, Y. C., Ban, Y., and Liu, L. F. (2007) Topoisomerase IIβ mediated DNA double-strand breaks: Implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. Cancer Res. 67, 8839-8846.
32. Drake, F. H., Hofmann, G. A., Bartus, H. F., Mattern, M. R., Crooke, S. T., and Mirabelli, C. K. (1989) Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II. Biochemistry 28, 8154-8160.
33. Willmore, E., Frank, A. J., Padget, K., Tilby, M. J., and Austin, C. A. (1998) Etoposide targets topoisomerase IIα and IIβ in leukemic cells: Isoform-specific cleavable comlexes visualized and quantified in situ by a novel immunofluorescence technique. Mol. Pharmacol. 53, 78-85.
34. Lopez-Lazaro, M., Willmore, E., and Austin, C. A. (2007) Cells lacking DNA topoisomerase IIβ are resistant to genistein. J. Nat. Prod. 70, 763-767.
35. Bender, R. P., Jablonksy, M. J., Shadid, M., Romaine, I., Dunlap, N., Anklin, C., Graves, D. E., and Osheroff, N. (2008) Substituents on etoposide that interact with human topoisomerase IIα in the binary enzyme-drug complex: Contributions to etoposide binding and activity. Biochemistry 47, 4501-4509.
36. Worland, S. T., and Wang, J. C. (1989) Inducible overexpression, purification, and active site mapping of DNA topoisomerase II from the yeast Saccharomyces cerevisiae. J. Biol. Chem. 264, 4412-4416.
37. Elsea, S. H., Hsiung, Y., Nitiss, J. L., and Osheroff, N. (1995) A yeast type II topoisomerase selected for resistance to quinolones. Mutation of histidine 1012 to tyrosine confers resistance to nonintercalative drugs but hypersensitivity to ellipticine. J. Biol. Chem. 270, 1913-1920.
38. Kingma, P. S., Greider, C. A., and Osheroff, N. (1997) Spontaneous DNA lesions poison human topoisomerase IIα and stimulate cleavage proximal to leukemic 11q23 chromosomal breakpoints. Biochemistry 36, 5934-5939.
39. Bradford, M. M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248-254.
40. Fortune, J. M., and Osheroff, N. (1998) Merbarone inhibits the catalytic activity of human topoisomerase IIα by blocking DNA cleavage. J. Biol. Chem. 273, 17643-17650.
41. Rogakou, E. P., Pilch, D. R., Orr, A. H., Ivanova, V. S., and Bonner, W. M. (1998) DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J. Biol. Chem. 276, 5858-5868.
42. Burma, S., Chen, B. P., Murphy, M., Kurimasa, A., and Chen, D. J. (2001) ATM phosphorylates histone H2AX in response to DNA double-strand breaks. J. Biol. Chem. 276, 42462-42467.
43. Byl, J. A., Cline, S. D., Utsugi, T., Kobunai, T., Yamada, Y., and Osheroff, N. (2001) DNA topoisomerase II as the target for the anticancer drug TOP-53: Mechanistic basis for drug action. Biochemistry 40, 712-718.
44. Geahlen, R. L., Koonchanok, N. M., McLaughlin, J. L., and Pratt, D. E. (1989) Inhibition of protein-tyrosine kinase activity by flavanoids and related compounds. J. Nat. Prod. 52, 982-986.
45. Meeran, S. M., and Katiyar, S. K. (2008) Cell cycle control as a basis for cancer chemoprevention through dietary agents. Front. Biosci. 13, 2191-2202.
46. Banerjee, S., Li, Y., Wang, Z., and Sarkar, F. H. (2008) Multitargeted therapy of cancer by genistein. Cancer Lett. 269, 226-242.
47. Mao, Y., Desai, S. D., Ting, C. Y., Hwang, J., and Liu, L. F. (2001) 26 S proteasome-mediated degradation of topoisomerase II cleavable complexes. J. Biol. Chem. 276, 40652-40658.
48. Xiao, H., Mao, Y., Desai, S. D., Zhou, N., Ting, C. Y., Hwang, J., and Liu, L. F. (2003) The topoisomerase IIβ circular clamp arrests transcription and signals a 26S proteasome pathway. Proc. Natl. Acad. Sci. U.S.A. 100, 3239-3244.
49. Zhang, A., Lyu, Y. L., Lin, C. P., Zhou, N., Azarova, A. M., Wood, L. M., and Liu, L. F. (2006) A protease pathway for the repair of topoisomerase II-DNA covalent complexes. J. Biol. Chem. 281, 35997-36003.
50. Lee, D. H., and Goldberg, A. L. (1996) Selective inhibitors of the proteasome-dependent and vacuolar pathways of protein degradation in Saccharomyces cerevisiae. J. Biol. Chem. 271, 27280-27284.
51. Lee, D. H., and Goldberg, A. L. (1998) Proteasome inhibitors: Valuable new tools for cell biologists. Trends Cell Biol. 8, 397-403.
52. Heck, M. M., Hittelman, W. N., and Earnshaw, W. C. (1988) Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle. Proc. Natl. Acad. Sci. U.S.A. 85, 1086-1090.
53. Hsiang, Y. H., Wu, H. Y., and Liu, L. F. (1988) Proliferation-dependent regulation of DNA topoisomerase II in cultured human cells. Cancer Res. 48, 3230-3235.
54. Woessner, R. D., Mattern, M. R., Mirabelli, C. K., Johnson, R. K., and Drake, F. H. (1991) Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. Cell Growth Differ. 2, 209-214.
55. Isaacs, R. J., Davies, S. L., Sandri, M. I., Redwood, C., Wells, N. J., and Hickson, I. D. (1998) Physiological regulation of eukaryotic topoisomerase II. Biochim. Biophys. Acta 1400, 121-137.
56. Austin, C. A., and Marsh, K. L. (1998) Eukaryotic DNA topoisomerase IIβ. BioEssays 20, 215-226.
57. Megonigal, M. D., Fertala, J., and Bjornsti, M. A. (1997) Alterations in the catalytic activity of yeast DNA topoisomerase I result in cell cycle arrest and cell death. J. Biol. Chem. 272, 12801-12808.
58. Fiorani, P., and Bjornsti, M. A. (2000) Mechanisms of DNA topoisomerase I-induced cell killing in the yeast Saccharomyces cerevisiae. Ann. N.Y. Acad. Sci. 922, 65-75.
59. Tanizawa, A., Kohn, K. W., Kohlhagen, G., Leteurtre, F., and Pommier, Y. (1995) Differential stabilization of eukaryotic DNA topoisomerase I cleavable complexes by camptothecin derivatives. Biochemistry 34, 7200-7206.
60. Capranico, G., and Binaschi, M. (1998) DNA sequence selectivity of topoisomerases and topoisomerase poisons. Biochim. Biophys. Acta 1400, 185-194.